Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America
Most prostate cancer patients who undergo androgen-deprivation therapy or orchiectomy will eventually develop castration-resistant prostate cancer (CRPC), often preceded by a nonmetastatic CRPC state known as M0CRPC. The recent development of second-generation antiandrogens provides clinicians with...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2021-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2021/3334333 |
| _version_ | 1798035164336488448 |
|---|---|
| author | Ray Manneh Ricardo Brugés Jose Jaime Correa Julián Rojas Daniel Rojas Nicolás Villareal |
| author_facet | Ray Manneh Ricardo Brugés Jose Jaime Correa Julián Rojas Daniel Rojas Nicolás Villareal |
| author_sort | Ray Manneh |
| collection | DOAJ |
| description | Most prostate cancer patients who undergo androgen-deprivation therapy or orchiectomy will eventually develop castration-resistant prostate cancer (CRPC), often preceded by a nonmetastatic CRPC state known as M0CRPC. The recent development of second-generation antiandrogens provides clinicians with efficacious and safe treatments for M0CRPC. However, the complexity of these patients, who typically have to deal with underlying comorbidities and polypharmacy, often challenges therapeutic decisions in this setting. The recent development of novel imaging techniques also provides clinicians with tools for detecting metastases with high sensitivity and specificity. However, the lack of evidence on the early detection of metastases and the corresponding impact on therapeutic decisions makes these techniques a double-edged sword that must be managed appropriately. Here, we present the expert view of the rapidly evolving concept of M0CRPC and provide recommendations for the identification of these patients, the appropriate use of the emerging imaging modalities, and patients’ management, particularly considering their clinical complexity and the recent development of next-generation antiandrogens. |
| first_indexed | 2024-04-11T20:53:28Z |
| format | Article |
| id | doaj.art-28ebbd61bfad401985badd8042584f0b |
| institution | Directory Open Access Journal |
| issn | 2090-312X |
| language | English |
| last_indexed | 2024-04-11T20:53:28Z |
| publishDate | 2021-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj.art-28ebbd61bfad401985badd8042584f0b2022-12-22T04:03:45ZengHindawi LimitedProstate Cancer2090-312X2021-01-01202110.1155/2021/3334333Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South AmericaRay Manneh0Ricardo Brugés1Jose Jaime Correa2Julián Rojas3Daniel Rojas4Nicolás Villareal5Sociedad de Oncología y Hematología Del CesarDepartment of OncologyDepartment of UrologyDepartment of Nuclear Medicine and PET/CTServicio de UrologíaDivision of UrologyMost prostate cancer patients who undergo androgen-deprivation therapy or orchiectomy will eventually develop castration-resistant prostate cancer (CRPC), often preceded by a nonmetastatic CRPC state known as M0CRPC. The recent development of second-generation antiandrogens provides clinicians with efficacious and safe treatments for M0CRPC. However, the complexity of these patients, who typically have to deal with underlying comorbidities and polypharmacy, often challenges therapeutic decisions in this setting. The recent development of novel imaging techniques also provides clinicians with tools for detecting metastases with high sensitivity and specificity. However, the lack of evidence on the early detection of metastases and the corresponding impact on therapeutic decisions makes these techniques a double-edged sword that must be managed appropriately. Here, we present the expert view of the rapidly evolving concept of M0CRPC and provide recommendations for the identification of these patients, the appropriate use of the emerging imaging modalities, and patients’ management, particularly considering their clinical complexity and the recent development of next-generation antiandrogens.http://dx.doi.org/10.1155/2021/3334333 |
| spellingShingle | Ray Manneh Ricardo Brugés Jose Jaime Correa Julián Rojas Daniel Rojas Nicolás Villareal Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America Prostate Cancer |
| title | Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America |
| title_full | Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America |
| title_fullStr | Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America |
| title_full_unstemmed | Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America |
| title_short | Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America |
| title_sort | management of patients with nonmetastatic castration resistant prostate cancer recommendations of a multidisciplinary panel of experts from south america |
| url | http://dx.doi.org/10.1155/2021/3334333 |
| work_keys_str_mv | AT raymanneh managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica AT ricardobruges managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica AT josejaimecorrea managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica AT julianrojas managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica AT danielrojas managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica AT nicolasvillareal managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica |